PL3778897T3 - Terapie immunoonkolityczne - Google Patents
Terapie immunoonkolityczneInfo
- Publication number
- PL3778897T3 PL3778897T3 PL20189155.3T PL20189155T PL3778897T3 PL 3778897 T3 PL3778897 T3 PL 3778897T3 PL 20189155 T PL20189155 T PL 20189155T PL 3778897 T3 PL3778897 T3 PL 3778897T3
- Authority
- PL
- Poland
- Prior art keywords
- immuno
- oncolytic therapies
- oncolytic
- therapies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361868978P | 2013-08-22 | 2013-08-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3778897T3 true PL3778897T3 (pl) | 2024-04-02 |
Family
ID=52484194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20189155.3T PL3778897T3 (pl) | 2013-08-22 | 2014-08-22 | Terapie immunoonkolityczne |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US11478518B2 (pl) |
| EP (3) | EP4324918A3 (pl) |
| JP (3) | JP6912199B2 (pl) |
| KR (1) | KR102389240B1 (pl) |
| CN (1) | CN105658795B (pl) |
| AU (1) | AU2014308648B2 (pl) |
| CA (3) | CA3213683A1 (pl) |
| CY (1) | CY1126587T1 (pl) |
| DK (2) | DK3036329T3 (pl) |
| EA (1) | EA037582B1 (pl) |
| ES (2) | ES2971528T3 (pl) |
| FI (1) | FI3778897T3 (pl) |
| HR (1) | HRP20240078T1 (pl) |
| HU (1) | HUE066593T2 (pl) |
| IL (1) | IL243996A0 (pl) |
| LT (1) | LT3778897T (pl) |
| MD (2) | MD4748C1 (pl) |
| MX (1) | MX2016002257A (pl) |
| NZ (1) | NZ716825A (pl) |
| PE (1) | PE20160673A1 (pl) |
| PH (1) | PH12016500329A1 (pl) |
| PL (1) | PL3778897T3 (pl) |
| PT (1) | PT3778897T (pl) |
| RS (1) | RS65104B1 (pl) |
| SG (1) | SG11201600960PA (pl) |
| SI (1) | SI3778897T1 (pl) |
| SM (1) | SMT202400047T1 (pl) |
| WO (1) | WO2015027163A1 (pl) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014308648B2 (en) | 2013-08-22 | 2020-11-12 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Immuno-oncolytic therapies |
| WO2016144564A2 (en) | 2015-02-25 | 2016-09-15 | Memorial Sloan-Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| CN107847534B (zh) | 2015-04-17 | 2022-10-04 | 纪念斯隆凯特琳癌症中心 | Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用 |
| JP6452266B2 (ja) * | 2015-07-22 | 2019-01-16 | 国立大学法人鳥取大学 | ワクシニアウイルスの増殖・伝搬を増強する宿主制御因子 |
| HK1255192A1 (zh) * | 2015-09-08 | 2019-08-09 | Sillajen, Inc. | 表达细胞因子和羧酸酯酶的修饰的溶瘤痘苗病毒及其使用方法 |
| AU2016349632A1 (en) | 2015-11-07 | 2018-05-24 | Multivir Inc. | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| US10512662B2 (en) | 2016-02-25 | 2019-12-24 | Memorial Sloan Kettering Cancer Center | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy |
| US10736962B2 (en) | 2016-02-25 | 2020-08-11 | Memorial Sloan Kettering Cancer Center | Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors |
| EP3432863A4 (en) * | 2016-03-25 | 2019-11-13 | University of Pittsburgh - of The Commonwealth System of Higher Education | SYNTHETICALLY COVED VIRUS |
| EP3254692A1 (en) * | 2016-06-10 | 2017-12-13 | Ceva Sante Animale | Multivalent recombinant spv |
| AU2017298385A1 (en) | 2016-07-19 | 2019-03-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oncolytic viruses targeting STAT3 |
| WO2018057755A1 (en) * | 2016-09-21 | 2018-03-29 | Thorne Stephen H | High mobility group box i mutant |
| GB201616365D0 (en) | 2016-09-27 | 2016-11-09 | Helsingin Yliopisto | Non-genetic modification of enveloped viruses |
| CN110381997A (zh) | 2016-12-12 | 2019-10-25 | 茂体外尔公司 | 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物 |
| AU2018215558B2 (en) * | 2017-02-03 | 2023-05-25 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Oncolytic virus therapy |
| WO2018165161A1 (en) * | 2017-03-06 | 2018-09-13 | Novartis Ag | Methods and compositions for determining the potency of a therapeutic cellular composition |
| AU2018254626B2 (en) * | 2017-04-21 | 2023-12-21 | Sillajen, Inc. | Oncolytic vaccinia virus and checkpoint inhibitor combination therapy |
| US11242509B2 (en) | 2017-05-12 | 2022-02-08 | Memorial Sloan Kettering Cancer Center | Vaccinia virus mutants useful for cancer immunotherapy |
| JP7551496B2 (ja) | 2017-10-31 | 2024-09-17 | カリヴィル イムノセラピューティクス， インコーポレイテッド | 全身送達のためのプラットフォーム腫瘍溶解性ベクター |
| WO2019106205A1 (en) | 2017-12-01 | 2019-06-06 | Gerd Sutter | Immuno-modulated replication-efficient vaccinia virus strain |
| MX2020007010A (es) | 2018-01-05 | 2020-12-10 | Ottawa Hospital Res Inst | Vectores modificados de orthopoxvirus. |
| KR20200135986A (ko) | 2018-03-19 | 2020-12-04 | 멀티비르 인코포레이티드 | 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물 |
| US20220370527A1 (en) * | 2018-07-20 | 2022-11-24 | Ansun Biopharma, Inc. | Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment |
| MX2021003013A (es) | 2018-09-15 | 2021-08-11 | Memorial Sloan Kettering Cancer Center | Poxvirus recombinantes para inmunoterapia contra cáncer. |
| JP2022516006A (ja) * | 2018-12-21 | 2022-02-24 | オタワ ホスピタル リサーチ インスティチュート | 修飾オルソポックスウイルスベクター |
| CN113661236A (zh) * | 2019-01-07 | 2021-11-16 | 卡利威尔免疫治疗公司 | 治疗癌症的方法 |
| WO2020148612A1 (en) * | 2019-01-14 | 2020-07-23 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
| CA3129883A1 (en) * | 2019-02-14 | 2020-08-20 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
| CN120037270A (zh) * | 2019-08-26 | 2025-05-27 | 拜耳诺克斯有限公司 | 包含痘苗病毒和羟基脲作为活性成分的用于治疗癌症的药物组合物 |
| EP4045657A4 (en) * | 2019-10-16 | 2023-11-15 | KaliVir Immunotherapeutics, Inc. | MODIFIED EXTRACELLULAR ENCLOSED VIRUS |
| EP4061417A4 (en) * | 2019-11-20 | 2023-10-11 | University of Pittsburgh - of the Commonwealth System of Higher Education | VACCINIA VIRUSES AND METHOD FOR USING VACCINIA VIRUSES |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| CA3163805A1 (en) * | 2019-12-12 | 2021-06-17 | Ignite Immunotherapy, Inc. | Variant oncolytic vaccinia virus and methods of use thereof |
| AU2021205287A1 (en) * | 2020-01-09 | 2022-07-21 | Pfizer Inc. | Recombinant vaccinia virus |
| CA3170045A1 (en) * | 2020-03-06 | 2021-09-10 | Saumendra N. SARKAR | Irf modulator-expressing oncolytic viruses for treating cancer |
| EP4172323A1 (en) * | 2020-06-29 | 2023-05-03 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| PE20231175A1 (es) | 2020-11-19 | 2023-08-01 | Kalivir Immunotherapeutics Inc | Inmunoterapia oncolitica por remodelacion del microambiente tumoral |
| IL316712B2 (en) * | 2021-04-30 | 2025-12-01 | Kalivir Immunotherapeutics Inc | Oncolytic viruses for modified mhc expression |
| KR20240026507A (ko) * | 2021-06-29 | 2024-02-28 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도 |
| WO2023106839A1 (ko) * | 2021-12-07 | 2023-06-15 | 재단법인 아산사회복지재단 | Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도 |
| CN120676952A (zh) * | 2022-07-08 | 2025-09-19 | 维罗米梭公司 | 溶瘤痘苗病毒及其重组病毒和使用方法 |
| WO2025251079A1 (en) * | 2024-05-31 | 2025-12-04 | University Of Massachusetts | Rna compositions and methods of use thereof in the treatment of cancer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9305855A (es) | 1992-09-24 | 1995-01-31 | Tadatsugu Taniguchi | Factores 1 y 2 reguladores del interferon en el diagnostico de latumorigenicidad. |
| WO2000073479A1 (en) | 1999-05-28 | 2000-12-07 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector |
| JP3986439B2 (ja) | 2001-02-07 | 2007-10-03 | 中外製薬株式会社 | 造血器腫瘍の治療剤 |
| EP2269619A1 (en) * | 2002-08-12 | 2011-01-05 | Jennerex Biotherapeutics ULC | Methods and compositions concerning poxviruses and cancer |
| WO2007023725A1 (ja) * | 2005-08-25 | 2007-03-01 | Yokohama City University | 遺伝子ワクチン |
| AU2012244210B2 (en) * | 2005-09-07 | 2014-10-02 | Sillajen Biotherapeutics, Inc. | Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses |
| US8980246B2 (en) * | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
| CN101351213B (zh) | 2005-09-07 | 2013-10-02 | 詹纳里克斯公司 | 使用表达gm-csf的痘病毒系统性治疗转移性癌和/或全身散布性癌 |
| KR20080084528A (ko) | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
| WO2009124044A2 (en) * | 2008-03-31 | 2009-10-08 | University Of Florida Research Foundation, Inc. | Tumor growth inhibition via conditioning of tumor microenvironment |
| ES2671570T3 (es) | 2009-09-14 | 2018-06-07 | Sillajen Biotherapeutics, Inc. | Terapia combinada contra el cáncer con virus oncolítico de vaccinia |
| WO2011119925A2 (en) * | 2010-03-25 | 2011-09-29 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthetic herpes simplex viruses for treatment of cancers |
| CN114262690A (zh) * | 2011-04-15 | 2022-04-01 | 吉恩勒克斯公司 | 减毒的痘苗病毒的克隆毒株及其使用方法 |
| US20150250837A1 (en) * | 2012-09-20 | 2015-09-10 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
| AU2014308648B2 (en) | 2013-08-22 | 2020-11-12 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Immuno-oncolytic therapies |
-
2014
- 2014-08-22 AU AU2014308648A patent/AU2014308648B2/en active Active
- 2014-08-22 CA CA3213683A patent/CA3213683A1/en active Pending
- 2014-08-22 CA CA3213715A patent/CA3213715A1/en active Pending
- 2014-08-22 RS RS20240082A patent/RS65104B1/sr unknown
- 2014-08-22 EP EP23215391.6A patent/EP4324918A3/en not_active Withdrawn
- 2014-08-22 EP EP14837931.6A patent/EP3036329B1/en active Active
- 2014-08-22 JP JP2016536482A patent/JP6912199B2/ja active Active
- 2014-08-22 MD MDA20180086A patent/MD4748C1/ro active IP Right Grant
- 2014-08-22 PE PE2016000287A patent/PE20160673A1/es unknown
- 2014-08-22 KR KR1020167006785A patent/KR102389240B1/ko active Active
- 2014-08-22 MX MX2016002257A patent/MX2016002257A/es unknown
- 2014-08-22 SM SM20240047T patent/SMT202400047T1/it unknown
- 2014-08-22 DK DK14837931.6T patent/DK3036329T3/da active
- 2014-08-22 SI SI201432060T patent/SI3778897T1/sl unknown
- 2014-08-22 CA CA2921041A patent/CA2921041C/en active Active
- 2014-08-22 PT PT201891553T patent/PT3778897T/pt unknown
- 2014-08-22 EA EA201690444A patent/EA037582B1/ru unknown
- 2014-08-22 NZ NZ716825A patent/NZ716825A/en unknown
- 2014-08-22 LT LTEP20189155.3T patent/LT3778897T/lt unknown
- 2014-08-22 SG SG11201600960PA patent/SG11201600960PA/en unknown
- 2014-08-22 HU HUE20189155A patent/HUE066593T2/hu unknown
- 2014-08-22 ES ES20189155T patent/ES2971528T3/es active Active
- 2014-08-22 CN CN201480058401.0A patent/CN105658795B/zh active Active
- 2014-08-22 DK DK20189155.3T patent/DK3778897T3/da active
- 2014-08-22 FI FIEP20189155.3T patent/FI3778897T3/fi active
- 2014-08-22 WO PCT/US2014/052308 patent/WO2015027163A1/en not_active Ceased
- 2014-08-22 MD MD20160027A patent/MD4624C1/ro active IP Right Grant
- 2014-08-22 ES ES14837931T patent/ES2847305T3/es active Active
- 2014-08-22 EP EP20189155.3A patent/EP3778897B1/en active Active
- 2014-08-22 PL PL20189155.3T patent/PL3778897T3/pl unknown
- 2014-08-22 HR HRP20240078TT patent/HRP20240078T1/hr unknown
-
2016
- 2016-02-07 IL IL243996A patent/IL243996A0/en unknown
- 2016-02-18 PH PH12016500329A patent/PH12016500329A1/en unknown
- 2016-02-19 US US15/048,698 patent/US11478518B2/en active Active
-
2019
- 2019-07-19 JP JP2019133264A patent/JP7021154B2/ja active Active
-
2022
- 2022-02-03 JP JP2022015459A patent/JP7333431B2/ja active Active
- 2022-09-07 US US17/939,707 patent/US12514888B2/en active Active
-
2024
- 2024-01-30 CY CY20241100073T patent/CY1126587T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL243996A0 (en) | Immuno-oncolytic treatments | |
| DK3689865T3 (en) | Hidtil ukendte aminopyrimidinderivater | |
| DK3088517T3 (en) | Humant anti-il-33-neutraliserende monoklonalt antistof | |
| DK3736291T3 (en) | Anti-FCRH5-antistoffer | |
| DK3354246T3 (en) | Udstyrsmonteringssystem | |
| DK3077519T3 (en) | Cmv-vacciner | |
| DK3470074T3 (en) | Probiotika | |
| AU353575S (en) | Stamphousing | |
| DK2979701T3 (en) | Antitumormiddel indbefattende irinotecanhydrochloridhydrat | |
| EP3014557A4 (en) | TELEPHONE ON FILE | |
| GB201300001D0 (en) | Envirep - environment replicater | |
| DK2989854T3 (en) | Strømstyret opvarmningssystem | |
| AU4899P (en) | Herbie53 Iresine herbstii | |
| AU4953P (en) | Flogazora Gazania rigens | |
| AU4977P (en) | Harrosy Gaura lindheimeri | |
| AU353329S (en) | Kettlebell | |
| AU353330S (en) | Kettlebell | |
| AU353328S (en) | Kettlebell | |
| AU353326S (en) | Kettlebell | |
| AU353327S (en) | Kettlebell | |
| AP00812S1 (en) | Stumbelbloc | |
| AU2013231V (en) | Bonsca7200 Scaevola aemula | |
| AU353341S (en) | Playsuit | |
| GB201313320D0 (en) | Hand-eze | |
| AU354283S (en) | Playsuit |